EGFR and non-small cell lung carcinoma: Among them, osimertinib (AZD9291) stands out as a representative compound widely approved for the standard second-line therapy of NSCLC with EGFR T790M mutation and first-line treatment in NSCLC with EGFR activating mutations.2 Additionally, ASK120067 is a novel third-generation EGFR TKI with promising antitumor efficacy reported by our team and is currently undergoing the New Drug Application (NDA) submission in China.3 Despite the marked preclinical and clinical efficacy of third-generation EGFR TKIs, acquired resistance inevitably develops.